
Hongying Gao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/37427/publications.pdf Version: 2024-02-01



HONCYING GAO

#	Article	IF	CITATIONS
1	Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. Nature Chemical Biology, 2021, 17, 567-575.	8.0	76
2	Design, synthesis, and biological evaluation of multiple targeting antimalarials. Acta Pharmaceutica Sinica B, 2021, 11, 2900-2913.	12.0	3
3	Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection in vitro. Antiviral Research, 2021, 194, 105161.	4.1	6
4	Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs. ACS Medicinal Chemistry Letters, 2020, 11, 1855-1862.	2.8	50
5	Global PROTAC Toolbox for Degrading BCR–ABL Overcomes Drug-Resistant Mutants and Adverse Effects. Journal of Medicinal Chemistry, 2020, 63, 8567-8583.	6.4	52
6	PROTAC Technology: Opportunities and Challenges. ACS Medicinal Chemistry Letters, 2020, 11, 237-240.	2.8	169
7	Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase. Journal of Medicinal Chemistry, 2020, 63, 4908-4928.	6.4	38
8	FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice. Protein and Cell, 2020, 11, 534-539.	11.0	24
9	Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. Journal of Medicinal Chemistry, 2019, 62, 7575-7582.	6.4	127
10	PROTACs: great opportunities for academia and industry. Signal Transduction and Targeted Therapy, 2019, 4, 64.	17.1	367
11	Synthesis of Quaternary Carbon-Centered Benzoindolizidinones via Novel Photoredox-Catalyzed Alkene Aminoarylation: Facile Access to Tylophorine and Analogues. CCS Chemistry, 2019, 1, 352-364.	7.8	10
12	Developing Equipotent Teixobactin Analogues against Drug-Resistant Bacteria and Discovering a Hydrophobic Interaction between Lipid II and Teixobactin. Journal of Medicinal Chemistry, 2018, 61, 3409-3421.	6.4	35
13	PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Research, 2018, 28, 779-781.	12.0	215
14	Synthesis and evaluation of osimertinib derivatives as potent EGFR inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 4553-4559.	3.0	13